Ignite Creation Date:
2025-12-25 @ 2:22 AM
Ignite Modification Date:
2026-02-27 @ 11:20 AM
Study NCT ID:
NCT03011034
Status:
COMPLETED
Last Update Posted:
2025-03-04
First Post:
2017-01-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Sponsor:
Janssen Research & Development, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-02-14
Start Date Type:
ACTUAL
Primary Completion Date:
2019-01-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-10-05
Completion Date Type:
ACTUAL
First Submit Date:
2017-01-04
First Submit QC Date:
None
Study First Post Date:
2017-01-05
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-01-20
Results First Submit QC Date:
None
Results First Post Date:
2020-03-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-03
Last Update Post Date:
2025-03-04
Last Update Post Date Type:
ACTUAL